HiMedia Laboratories Pvt. Ltd. has been providing quality products and solutions at affordable prices for almost five decades to our esteemed patrons in over 150 countries all over the world.
A simpler strategy of HiMedia–innovation, affordability, accessibility and Make in India continue to be our roadmap for becoming India’s leading bioscience supplier company. HiMedia plays a major role in impacting our scientists and professionals in the bioscience field through wider accessibility and greater affordability. In the bioscience supplier domain, HiMedia is the only indigenous company in India to have an extensive sales and services network, supporting governmental, academic, and private organizations through over 300 Tier I–IV cities, towns, and villages throughout the country. To achieve broader coverage, HiMedia also has a network of more than 300 channel partners. By adopting cutting-edge technology and customizing it to cater to the Indian and global markets, we add innovative products and solutions every year to our pricelist. The innovation is also due to our multidisciplinary portfolio, which covers the seven key domains of biosciences, such as microbiology, cell biology, molecular biology, plant tissue culture, chemicals and biochemicals, laboratory consumables and instruments, and hydroponics. Information technology at HiMedia is doing exciting implementations, using RFID-enabled smart warehouse, smart laboratory (IoT), and smart invoicing while also developing new products based on AI and machine learning.
Having said that, we continue to focus on both organic and inorganic growth to serve emerging markets. Today, 48 years later, HiMedia has changed the landscape of microbiology business in India. We are now, ranked among the top three media manufacturers in the world by the American Society of Microbiology (Ref. Handbook of Microbiology Media, 4th Edition, Prof. Ronald Atlas, ASM, CRC Press). This is the kind of recognition that drives HiMedia every single day to make science easy. We had the opportunity to serve our country and the rest of the world during Covid-19 in 2020 and 2021. We ramped up our facilities by several folds to provide 70 million viral transport medium tests and 56 million RNA extraction kits.
Looking at the trends in healthcare industry, we are sure the next 3–5 years will be more demanding for rapid-detection kind of products. This is especially true in light of the Covid-19 pandemic. With increasing demand in the USFDA-approved pharmaceutical industry, there was an intense need for ready-prepared media plates and reagents, and we foresee this opportunity to ramp up our capacity to provide the same. On the microbiology research side, microbiome research has increased dramatically in recent years, driven by advances in technology and significant reductions in the cost of analysis. Such research has unlocked a wealth of data. Considering this trend in technology, we focused on services of genomic sequencing, microbial identification, and microbiome research to develop prebiotics, probiotics, and postbiotics. In the future, medical biotechnology will contribute to the normalization of personalized medicine by virtue of pharmacogenomics and high-throughput nucleic acid sequencing. At HiMedia, we are using stem cells to create personalized cell organoids, which along with tissue engineering will aid in organ transplantation. We have focused more on the global collaborations for cutting-edge research and new products development in the field of cultured meat, BioInks for 3D bioprinting, development and manufacture of recombinant proteins, clone development, and chemically defined serum-free media and feed for mAb productions. Our molecular biology wing has a diverse product palette, which is used in areas of genomics, proteomics, instrumentation and genomic sequencing and bioinformatics services. We have developed niche IT software, based on forensic human identification, thereby driving the country toward being Atmanirbhar for the increasingly growing molecular diagnostic sector. The rich legacy of spirit of innovation is successfully being continued.